WO2006010106A3 - Vaccination par adn de sujets atteints d'un retrovirus et suivant un traitement - Google Patents

Vaccination par adn de sujets atteints d'un retrovirus et suivant un traitement Download PDF

Info

Publication number
WO2006010106A3
WO2006010106A3 PCT/US2005/024498 US2005024498W WO2006010106A3 WO 2006010106 A3 WO2006010106 A3 WO 2006010106A3 US 2005024498 W US2005024498 W US 2005024498W WO 2006010106 A3 WO2006010106 A3 WO 2006010106A3
Authority
WO
WIPO (PCT)
Prior art keywords
retroviral
dna
undergoing treatment
infected individuals
individuals undergoing
Prior art date
Application number
PCT/US2005/024498
Other languages
English (en)
Other versions
WO2006010106A2 (fr
Inventor
Barbara Felber
George N Pavlakis
Original Assignee
Human Services D By The Secret
Barbara Felber
George N Pavlakis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Services D By The Secret, Barbara Felber, George N Pavlakis filed Critical Human Services D By The Secret
Priority to US11/571,879 priority Critical patent/US20090169503A1/en
Publication of WO2006010106A2 publication Critical patent/WO2006010106A2/fr
Publication of WO2006010106A3 publication Critical patent/WO2006010106A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à des vaccins à ADN destinés à traiter des patients suivant un traitement antirétroviral. Les vaccins selon l'invention permettent de lutter particulièrement efficacement contre la virémie.
PCT/US2005/024498 2004-07-09 2005-07-11 Vaccination par adn de sujets atteints d'un retrovirus et suivant un traitement WO2006010106A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/571,879 US20090169503A1 (en) 2004-07-09 2005-07-11 Dna-based vaccination of retroviral-infected individuals undergoing treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58653904P 2004-07-09 2004-07-09
US60/586,539 2004-07-09

Publications (2)

Publication Number Publication Date
WO2006010106A2 WO2006010106A2 (fr) 2006-01-26
WO2006010106A3 true WO2006010106A3 (fr) 2006-06-01

Family

ID=35500669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024498 WO2006010106A2 (fr) 2004-07-09 2005-07-11 Vaccination par adn de sujets atteints d'un retrovirus et suivant un traitement

Country Status (2)

Country Link
US (1) US20090169503A1 (fr)
WO (1) WO2006010106A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008089144A2 (fr) * 2007-01-12 2008-07-24 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Protocoles améliorés de vaccination par adn
US9181306B2 (en) * 2009-10-16 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
WO2011106705A2 (fr) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protocoles de vaccination adn/protéine
EP2620446A1 (fr) * 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogènes pour la vaccination contre le VIH
EP3168306A1 (fr) 2015-11-16 2017-05-17 ChromoTek GmbH Marqueur d'épitope et procédé de détection et/ou de purification de polypeptides marqués
WO2017201079A1 (fr) * 2016-05-16 2017-11-23 Biomadison, Inc. Essai amélioré avec un fragment à base de synaptobrévine
US12019066B2 (en) 2016-05-16 2024-06-25 Biomadison, Inc. Assay with synaptobrevin based moiety
EP4058058A1 (fr) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Régimes posologiques pour vaccins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001008702A2 (fr) * 1999-07-28 2001-02-08 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie
WO2002036806A2 (fr) * 2000-11-01 2002-05-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vecteurs d'expression permettant de provoquer une reponse immunitaire et procedes d'utilisation desdits vecteurs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US20040034209A1 (en) * 2001-01-26 2004-02-19 David Ho Vaccination of hiv infected persons following highly active antiretrovial therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001008702A2 (fr) * 1999-07-28 2001-02-08 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie
WO2002036806A2 (fr) * 2000-11-01 2002-05-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vecteurs d'expression permettant de provoquer une reponse immunitaire et procedes d'utilisation desdits vecteurs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEL Z ET AL: "Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques.", NATURE MEDICINE. OCT 2000, vol. 6, no. 10, October 2000 (2000-10-01), pages 1140 - 1146, XP000982290, ISSN: 1078-8956 *
ROSATI MARGHERITA ET AL: "DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge", JOURNAL OF VIROLOGY, vol. 79, no. 13, July 2005 (2005-07-01), pages 8480 - 8492, XP002373828, ISSN: 0022-538X *
TRYNISZEWSKA ELZBIETA ET AL: "Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 NOV 2002, vol. 169, no. 9, 1 November 2002 (2002-11-01), pages 5347 - 5357, XP002373830, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2006010106A2 (fr) 2006-01-26
US20090169503A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
WO2008089144A3 (fr) Protocoles améliorés de vaccination par adn
WO2006010106A3 (fr) Vaccination par adn de sujets atteints d'un retrovirus et suivant un traitement
EP2308885A3 (fr) Nouveaux composés et procédés pour la thérapie
SG149075A1 (en) Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
WO2006089001A3 (fr) Vecteurs lentiviraux et leurs utilisations
WO2009070294A3 (fr) Inhibition du récepteur de la protéine stimulant les macrophages (ron) et procédés de traitement
HK1083866A1 (en) Hla-a24-restricted cancer antigen peptides hla-a24
WO2004022580A3 (fr) Peptides bh3 et leur methode d'utilisation
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2009099677A3 (fr) Macrocycles peptidomimétiques thérapeutiques
HK1207821A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
WO2007030810A3 (fr) Moniteur de sang total multiparametrique et procede associe
WO2001083729A3 (fr) Vecteurs pour transduction oculaire et utilisation en therapie genique
WO2003083041A3 (fr) Anticorps specifiques au cripto
WO2006020773A3 (fr) Procedes permettant de preparer des plaquettes lyophilisees, compositions contenant lesdites plaquettes lyophilisees, et procedes d'utilisation associes
WO2006023544A3 (fr) Applications therapeutiques d'inhibiteurs de rtp801
EP1740262A4 (fr) Systeme de traitement de tissu microchirurgical
ATE395871T1 (de) Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
WO2006014999A3 (fr) Compositions et methodes d'utilisation de modulateurs de nectine 4, de semaphorine 4b, d'igsf9 et de kiaa0152 dans le traitement de maladies
EP1961447A3 (fr) traitement de troubles depressifs avec des activateurs de la pkc
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
WO2007109799A3 (fr) Polymorphes de malate d'eszopiclone
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 11571879

Country of ref document: US